Athira Pharma Inc reports results for the quarter ended in March - Earnings Summary

LeonaBio

15/05/2024 22:18

* Athira Pharma Inc  ATHA.OQ  reported a quarterly adjusted
loss
of 69 cents​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of -73 cents.  The mean expectation of five analysts for the
quarter was for a loss of 79 cents per share. Wall Street
expected results to range from -86 cents to -73 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Athira Pharma Inc's reported EPS for the quarter was a
loss
of 69 cents​.
    * The company reported a quarterly loss of $26.34 million.
    * Athira Pharma Inc shares had fallen by 19.7% this
quarter and
lost 9.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 16.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Athira Pharma Inc
is $4.50 
This summary was machine generated from LSEG data May 15 at
09:17 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.79          -0.69          Beat
 Dec. 31 2023      -0.96          -0.71          Beat
 Sep. 30 2023      -0.81          -0.87          Missed
 Jun. 30 2023      -0.78          -0.78          Met